Cargando…

PARP-1 deregulation in multiple sclerosis

BACKGROUND: Poly (ADP-ribose) polymerase 1 (PARP-1) plays pivotal roles in immune and inflammatory responses. Accumulating evidence suggests PARP-1 as a promising target for immunomodulation in multiple sclerosis and natalizumab-associated progressive multifocal leukoencephalopathy. OBJECTIVE: This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meira, Maria, Sievers, Claudia, Hoffmann, Francine, Bodmer, Heidi, Derfuss, Tobias, Kuhle, Jens, Haghikia, Aiden, Kappos, Ludwig, Lindberg, Raija LP
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918498/ https://www.ncbi.nlm.nih.gov/pubmed/31897308 http://dx.doi.org/10.1177/2055217319894604

Ejemplares similares

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Brain atrophy measurement over a MRI scanner change in multiple sclerosis
por: Sinnecker, Tim, et al.
Publicado: (2022)

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
por: Zimmermann, Maria, et al.
Publicado: (2015)

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis
por: Cerdá-Fuertes, Nuria, et al.
Publicado: (2023)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
por: Diebold, Martin, et al.
Publicado: (2019)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

Impact of complement activation on clinical outcomes in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2021)

Multiple sclerosis and nutrition: back to the future?
por: Gold, Ralf, et al.
Publicado: (2020)

High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities
por: Rose, Natalie, et al.
Publicado: (2022)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Death Anxiety and Attitudes towards Death in Patients with Multiple Sclerosis: An Exploratory Study
por: Francalancia, Jara, et al.
Publicado: (2021)

Microstructure-Weighted Connectomics in Multiple Sclerosis
por: Bosticardo, Sara, et al.
Publicado: (2022)

Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-Therapy
por: Mehling, Matthias, et al.
Publicado: (2013)

Lymphocyte recovery after fingolimod discontinuation in patients with MS
por: Nagy, Sara, et al.
Publicado: (2020)

Effects of repetitive twice-weekly transcranial direct current stimulations on fatigue and fatigability in people with multiple sclerosis
por: Linnhoff, Stefanie, et al.
Publicado: (2023)

Personalized medicine in multiple sclerosis: hope or reality?
por: Derfuss, Tobias
Publicado: (2012)

Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis
por: Weier, Katrin, et al.
Publicado: (2014)

Functional and structural readouts for early detection of retinal involvement in multiple sclerosis
por: Al-Nosairy, Khaldoon O., et al.
Publicado: (2023)

Structure–Function Relationship of Retinal Ganglion Cells in Multiple Sclerosis
por: Al-Nosairy, Khaldoon O., et al.
Publicado: (2021)

Propionic acid beneficially modifies osteoporosis biomarkers in patients with multiple sclerosis
por: Duscha, Alexander, et al.
Publicado: (2022)

Quantified CSF antibody reactivity against myelin in multiple sclerosis
por: Sun, Xingwen, et al.
Publicado: (2015)

Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis
por: Cerdá-Fuertes, Nuria, et al.
Publicado: (2023)

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2017)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis
por: Vohl, Katja, et al.
Publicado: (2019)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
por: Chalkou, Konstantina, et al.
Publicado: (2021)

Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis
por: Gilli, Francesca, et al.
Publicado: (2010)

Western lifestyle and immunopathology of multiple sclerosis
por: Matveeva, Olga, et al.
Publicado: (2018)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

B Cells and Autoantibodies in Multiple Sclerosis
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_me0g7eksktao5jjgda4cgts2b0